DS Pharma Peru S.a.c. Pharmaceutical Import Profile — Peru (DGFT 2022–2026)

Name: DS Pharma Peru S.a.c. Pharmaceutical Import Records from India — 2 Products, $237.8K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

DS Pharma Peru S.a.c. — Pharmaceutical Importer Profile (2026) | 2 Products, $237.8K Trade | TransData Nexus

DS Pharma Peru S.a.c.

Pharmaceutical Importer · Peru · Oncology Focus · $237.8K Total Trade · DGFT Verified

DS Pharma Peru S.a.c. is a pharmaceutical importer based in Peru with a total trade value of $237.8K across 2 products in 2 therapeutic categories. Based on 10 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. DS Pharma Peru S.a.c. sources from 2 verified Indian suppliers, with Kwality Pharmaceuticals Limited accounting for 95.3% of imports.

DS Pharma Peru S.a.c. — Import Portfolio & Supplier Network

DS Pharma Peru S.a.c. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to DS Pharma Peru S.a.c.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Kwality Pharmaceuticals Limited	$441.6K	22	95.3%
Innova Captab Limited	$21.6K	2	4.7%

DS Pharma Peru S.a.c. sources from 2 verified Indian suppliers across .

What Formulations Does DS Pharma Peru S.a.c. Import?

Formulation	Value	Ships
Cyclophosphamide for injection BP 1000MG(batch no & other details as per inv &packing list)	$79.0K	2
Ifosfamide for injection USP 1GM(batch no & other details as per inv & packing list)	$50.0K	1
Docetaxel injection USP 80MG/2ML (batchno & other details as per inv & packinglist)	$49.8K	2
Ifosfamide for injection USP 1GM (batchno & other detail as per inv & packing list)	$39.6K	1
Irinotecan hydrochloride injection 100MG/5ML (batch no & other details as per inv & packing list)	$38.6K	2
Irinotecan hydrochloride injection (batch no & other details as per inv & packing list)	$36.2K	1
Docetaxel injection USP 80MG/2ML (batchno & other details as per inv & packinglist)	$22.9K	1
Cyclophosphamide for injection BP 1000MG(batch no & other details as per inv &packing list)	$17.6K	1
Cyclophosphamide for injection BP 1000MG(batch no & other detail as per inv & packing list)	$17.5K	1
Leuprolide acetate injection (batch no& other detail as per inv & packing list)	$14.5K	1
Ifosfamide for injection USP 1GM (batchno & other detail as per inv & packinglist	$13.7K	1
Cefazolina 1GM (tefazolina	$12.7K	1
Paclitaxel injection USP 100MG/16.7ML(dasataxel - paclitaxel injection USP 30MG/5ML )batch no & other detailas per inv	$12.5K	1
Abiraterone acetate tablets 250MG (batchno & other details as per inv & packinglist)	$12.2K	1
Leuprolide acetate injection (batch no& other details as per inv & packing list)	$11.8K	1

DS Pharma Peru S.a.c. imports 21 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cyclophosphamide	Oncology	$119.9K	6	0.6%	14
2	Ifosfamide	Advanced Oncology	$117.9K	4	4.8%	3

DS Pharma Peru S.a.c. imports 2 pharmaceutical products across 2 categories into Peru totaling $237.8K.

DS Pharma Peru S.a.c. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

DS Pharma Peru S.A.C., also known as DSPP S.A.C., is a Peruvian pharmaceutical importer and wholesaler specializing in the distribution of finished pharmaceutical formulations. Established on September 2, 2020, the company is headquartered at Calle Las Palmeras 184, Int. 6, San Isidro, Lima, Peru. As of February 2024, DSPP S.A.C. employed nine individuals and engaged ten service providers. The company's primary focus is on the wholesale distribution of pharmaceutical products, with a particular emphasis on oncology medications.

2Distribution Network

DSPP S.A.C. operates multiple facilities across Peru to support its distribution network. In addition to its main office in San Isidro, Lima, the company maintains establishments in Chorrillos and San Juan de Miraflores, both located in Lima. These locations enable DSPP S.A.C. to effectively manage logistics and ensure timely delivery of pharmaceutical products throughout the country.

3Industry Role

Within Peru's pharmaceutical supply chain, DSPP S.A.C. functions as a primary wholesaler and importer. The company sources finished pharmaceutical formulations from international suppliers, particularly from India, and distributes these products to various healthcare providers, including hospitals, clinics, and pharmacies. By focusing on the importation and wholesale distribution of oncology medications, DSPP S.A.C. plays a crucial role in ensuring the availability of essential cancer treatments in the Peruvian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — DS Pharma Peru S.a.c.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

DSPP S.A.C. demonstrates a high level of supplier concentration, with a significant majority of its imports originating from a single supplier, KWALITY PHARMACEUTICALS LIMITED. Between 2022 and 2026, KWALITY PHARMACEUTICALS LIMITED accounted for 95.3% of DSPP S.A.C.'s shipments, totaling $442,000 across 22 shipments. This reliance on a single supplier may pose risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent volume of shipments suggests a stable and ongoing relationship between DSPP S.A.C. and KWALITY PHARMACEUTICALS LIMITED.

2Supply Chain Resilience

The resilience of DSPP S.A.C.'s supply chain is closely tied to its dependence on KWALITY PHARMACEUTICALS LIMITED. The company's limited engagement with other suppliers, such as INNOVA CAPTAB LIMITED, which accounted for only 4.7% of shipments, indicates a lack of diversification in sourcing. This concentration could expose DSPP S.A.C. to risks if KWALITY PHARMACEUTICALS LIMITED faces operational challenges. Additionally, the absence of backup suppliers and limited formulation diversity may further compromise supply chain stability.

3Strategic Implications

Importing Pharmaceuticals into Peru — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Peru

1Regulatory Authority & Framework

In Peru, the regulatory authority overseeing pharmaceutical imports is the General Directorate of Medicines, Supplies, and Drugs (DIGEMID), which operates under the Ministry of Health. DIGEMID is responsible for the registration, control, and surveillance of pharmaceutical products, ensuring they meet safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Law on Pharmaceuticals, Medical Devices, and Sanitary Products (Law N° 29459) and its corresponding regulations. The marketing authorization pathway for Indian generics involves obtaining registration from DIGEMID, which requires submission of comprehensive documentation, including evidence of Good Manufacturing Practices (GMP) compliance.

2Import Licensing & GMP

Import licensing in Peru necessitates that foreign manufacturers possess a valid GMP certificate recognized by DIGEMID. Peru acknowledges GMP certifications from reputable authorities, such as the World Health Organization (WHO) and the European Union (EU). Indian exporters seeking to supply DSPP S.A.C. must ensure their manufacturing facilities are compliant with these recognized GMP standards. Additionally, DSPP S.A.C. must hold a wholesale distribution authorization from DIGEMID to legally distribute pharmaceutical products within Peru.

DS Pharma Peru S.a.c. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

DSPP S.A.C. focuses on importing oncology medications, specifically cyclophosphamide and ifosfamide, which constitute 50.4% and 49.6% of its total imports, respectively. This strategic emphasis aligns with the high demand for cancer treatments in Peru, where access to effective therapies is critical. The company's product strategy is driven by the need to provide essential medications to meet the therapeutic requirements of oncology patients in the Peruvian healthcare system.

2Sourcing Profile

DSPP S.A.C. primarily sources generic oncology drugs from India, focusing on formulations such as cyclophosphamide and ifosfamide. India's robust pharmaceutical manufacturing sector, characterized by compliance with international GMP standards, makes it a preferred sourcing destination for DSPP S.A.C. This sourcing strategy enables the company to offer cost-effective and high-quality oncology medications to the Peruvian market.

3Market Positioning

By importing and distributing oncology medications, DSPP S.A.C. serves the hospital and clinic segments of the Peruvian healthcare market. The company's focus on essential cancer treatments positions it as a critical supplier to healthcare providers involved in oncology care, ensuring the availability of necessary medications for patient treatment regimens.

Seller's Guide — How to Become a Supplier to DS Pharma Peru S.a.c.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Peruvian market by offering alternative sources of oncology medications. Diversifying DSPP S.A.C.'s supplier base could mitigate risks associated with supplier dependency and enhance supply chain resilience. Identifying gaps in DSPP S.A.C.'s current sourcing, such as the need for additional formulations or competitive pricing, presents avenues for new suppliers to establish partnerships.

2Requirements & Qualifications

Indian exporters aiming to supply DSPP S.A.C. must ensure their manufacturing facilities are compliant with recognized GMP standards, such as those set by the WHO or EU. Products must meet Peruvian quality and labeling requirements, including batch testing, stability, and Spanish-language labeling. Additionally, exporters should be prepared to navigate the regulatory processes of DIGEMID to obtain the necessary approvals for marketing authorization in Peru.

3How to Approach

Frequently Asked Questions — DS Pharma Peru S.a.c.

What products does DS Pharma Peru S.a.c. import from India?

DS Pharma Peru S.a.c. imports 2 pharmaceutical products across 2 categories. Top imports: Cyclophosphamide ($119.9K), Ifosfamide ($117.9K).

Who supplies pharmaceuticals to DS Pharma Peru S.a.c. from India?

DS Pharma Peru S.a.c. sources from 2 verified Indian suppliers. The primary supplier is Kwality Pharmaceuticals Limited (95.3% of imports, $441.6K).

What is DS Pharma Peru S.a.c.'s total pharmaceutical import value?

DS Pharma Peru S.a.c.'s total pharmaceutical import value from India is $237.8K, based on 10 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does DS Pharma Peru S.a.c. focus on?

DS Pharma Peru S.a.c. imports across 2 categories. The largest: Oncology (50.4%), Advanced Oncology (49.6%).

Get Full DS Pharma Peru S.a.c. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.